logo

Bellerophon Therapeutics Llc (BLPH)



Trade BLPH now with
  Date
  Headline
8/11/2020 8:38:56 AM Bellerophon Appoints Wassim Fares As Chief Medical Officer
7/13/2020 8:39:13 AM Bellerophon Says First Patient Treated In Phase 3 Study Of INOpulse INO Therapy For COVID-19
5/19/2020 7:20:43 AM Bellerophon Therapeutics Reports Pricing Of Offerings Of 3.08 Mln Shares At $13/Shr
4/8/2020 8:35:26 AM Bellerophon Therapeutics Submits IND To Study INOpulse Inhaled Nitric Oxide Therapy For COVID-19
3/30/2020 8:06:41 AM Bellerophon: First Patient Treated With INOpulse Inhaled Nitric Oxide Therapy For COVID-19
3/10/2020 8:37:14 AM Bellerophon Therapeutics Completes End-of-Phase 2 Meetings With FDA For INOpulse For PH-PF
12/17/2019 7:07:14 AM Bellerophon Announces Positive Top-line Results From Cohort 2 Of Ongoing Phase 2/3 Clinical Study Of INOpulse
9/16/2019 8:36:08 AM Bellerophon Therapeutics: FDA Granted Orphan Drug Designation To Nitric Oxide
9/16/2019 8:34:27 AM Bellerophon Receives Orphan Drug Designation For Nitric Oxide In The Treatment Of Idiopathic Pulmonary Fibrosis
8/1/2019 8:39:40 AM Bellerophon Completes Enrollment In Cohort 2 Of Phase 2/3 Study Of INOpulse
1/25/2019 4:11:08 PM Bellerophon Announces Closing Of $7 Mln Public Offering Of Common Stock
1/23/2019 6:01:35 AM Bellerophon Therapeutics Prices Public Offering Of 10 Mln Shares At $0.70 Per Share
1/22/2019 4:48:58 PM Bellerophon Therapeutics Announces Proposed Public Offering Of Common Stock